Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO

Kidney360. 2021 Apr 19;2(11):1696-1698. doi: 10.34067/KID.0001842021. eCollection 2021 Nov 25.

Authors

Nestor Oliva-Damaso¹, Andrew S Bomback²

Affiliations

¹ Department of Medicine, Hospital Costa del Sol, Marbella, Spain.
² Department of Medicine, Columbia University Irving Medical Center, New York, New York.

No abstract available

Keywords: cyclophosphamide; glomerular and tubulointerstitial diseases; immunosuppressive agents; membranous glomerulonephritis; rituximab.

MeSH terms

Cyclophosphamide / adverse effects
Glomerulonephritis, Membranous* / drug therapy
Humans
Receptors, Phospholipase A2
Rituximab / adverse effects

Substances

Receptors, Phospholipase A2
Rituximab
Cyclophosphamide